Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-010177

Options or other derivatives

  • Chief Scientific Officer acquired 187,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
SCIASCIA THOMAS Chief Scientific Officer 2023-02-16 Grant or award · Stock Option (right to buy) +187,500 187,500 D: show line 1 in the form
Loading xslF345X03/doc4.xml…